Ironwood Pharmaceuticals Inc (IRWD) — Who's Buying and Selling (13F, Q2 2026)

IRWD ranks #2848 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

IRWD is a top-conviction position for Sarissa Capital Management LP — at 21.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IRWD belongs to BlackRock, Inc., but the position matters far more to Sarissa Capital Management LP, who has 21.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its IRWD position for two straight quarters, increasing it by $31.8M to reach $74.9M today.

Jane Street Group, LLC has trimmed its IRWD position for two straight quarters, cutting it by $8.9M while still holding $613.0K.

IRWD is down 2.3% today, and institutions have been net sellers of $26.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

IRWD posted net income of $129.9M over the trailing twelve months, and currently trades at a P/E of 5.4.

• Profitable — net income of $129.9M over the trailing twelve months
• Revenue grew 26.2% year over year
• Net income improved year over year, from -$7.9M to $129.9M
• Generated $127.0M in positive operating cash flow
• Current ratio of 1.13x — below the conventional 1.5x liquidity buffer